Coriell Life Sciences case study: A DNA analysis and precision medicine algorithm generates a detailed personalized medicine report for participants of the Teachers’ Retirement System of the State of Kentucky.
A new analysis by University of Chicago Medicine faculty, staff and collaborators around the world found remdesivir appears to be equally beneficial to patients regardless of race, supporting the need for early intervention and aggressive care for all patients in the fight against COVID-19.
Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers.
Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against glioblastoma, a type of aggressive brain tumor.
By analyzing the FDA database of adverse drug effects, UC San Diego researchers discovered that people who received Botox injections — not just in the forehead — reported depression significantly less often than patients undergoing different treatments for the same conditions.
UPTON, NY—On July 29, 2020 the U.S. Department of Energy's (DOE) Brookhaven National Laboratory opened a new cryo-electron microscopy center, the Laboratory for BioMolecular Structure (LBMS), with an initial focus on COVID-19-related research. This state-of-the-art research center for life sciences imaging offers researchers access to advanced cryo-electron microscopes (cryo-EM)—funded by NY State—for studying complex proteins, as well as the architecture of cells and tissues.
A multi-institution phase 1b/2a clinical trial found good tolerability and encouraging efficacy data for a pan-BET bromodomain inhibitor in combination with enzalutamide.
In a pilot study of people living with HIV or high levels of cholesterol, Johns Hopkins Medicine researchers found that a six-week course of a cholesterol-lowering medication improved the function of the coronary arteries that provide oxygen to the heart.
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.
Even short, single antibiotic courses given to young animals can predispose them to inflammatory bowel disease (IBD) when they are older, according to Rutgers researchers.
They are used by 150 million women worldwide and have been around for over 60 years. Oral contraceptives - like birth control pills - are part of many women's lives, often starting during puberty and early adolescence.
BioMed Valley Discoveries (BVD), a clinical stage biotechnology company, announces the receipt of Fast Track designation from the US Food and Drug Administration (FDA) for investigation of the ERK inhibitor ulixertinib (BVD-523) as a treatment for patients with non-colorectal, solid tumors that harbor BRAF mutations G469A/V, L485W, or L597Q. BVD has launched a Phase II multi-center study of ulixertinib for patients with advanced malignancies harboring these atypical (non-V600) BRAF alterations or a MEK alteration.
Researchers have discovered a new drug candidate that offers a major advance to treat diabetes. Tested on human and mouse pancreatic islets, mouse and rat cell cultures and animal models of Type 1 and Type 2 diabetes, the drug significantly improved four detrimental characteristics of diabetes.
To fight antibiotic resistance more antimicrobials are needed to treat bacterial biofilms, which protect an infection from antibiotics
The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments. Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey participated in the pivotal trial which the approval was based: the ZUMA-2 clinical trial, which assessed the safety and effectiveness of brexucabtagene autoleucel in patients with relapsed or refractory MCL who had received up to five prior regimens of treatment and had exhausted all other therapies. That transformative study showed that 93% of patients responded to treatment, with 67% achieving a complete response (no evidence of disease). The data were published in the April 2, 2020 issue of the New England Journal of Medicine.
A team of UCLA neurologists have uncovered new potential drug targets in the brains of patients with Alzheimer’s disease, after testing more than a thousand patient samples
A Ludwig Cancer Research study has identified a new instance in which the simultaneous mutation of two nonessential genes—neither of which is on its own vital to cell survival—can cause cancer cell death.
Scientists have long been concerned that the common practice of medical journals accepting commercial payments from pharmaceutical companies may lead to pro-industry bias in published articles. According to new research at The University of Texas at Austin, scientists were right to be concerned, but they were focusing on the wrong type of payments. In a new article published by PLOS ONE, researchers reviewed 128,781 articles published in 159 different medical journals for markers of pro-industry bias, evaluating whether accepting advertising revenue, fulfilling reprint contracts or being owned by a large multinational publishing firm made a journal more likely to publish articles favorable to industry. They found that articles published in journals that accept reprint fees are nearly three times more likely to be written by authors who receive industry payments. “I was honestly surprised by the findings here,” said S. Scott Graham, lead author of the study and assistant professor of
Researchers at Nationwide Children’s Hospital analyzed 549,807 calls made to Poison Control Centers in the U.S. for suicide-related cases involving OTC analgesics from 2000-2018 and found that both the overall number and rate of these cases increased by 57% and 34%, respectively, during this period.
A Nature study authored by a global team of scientists and led by Sumit Chanda, Ph.D., professor at Sanford Burnham Prebys Medical Discovery Institute, has identified 21 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19.
Today’s Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online. Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. The research is the latest example of a decoy strategy researchers at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.
A new cell profiling technology combines high throughput imaging and machine learning to provide a rapid, cost-effective way to determine how specific compounds act to destroy the bacterium that causes tuberculosis. It could speed discovery of anti-TB drugs and be applied to other pathogens.
The NCCN Oncology Research Program (ORP) today announced four projects selected to receive funding for clinical and pre-clinical evaluation of futibatinib (TAS-120) in collaboration with Taiho Oncology.
PDE5 inhibitors, such as sildenafil, activate protein quality-control systems and improve cells’ ability to dispose of misfolded proteins. Researchers find lowered accumulation of mutant proteins and reduced cell death and anatomical defects in zebrafish models of neurodegeneration after treatment.
A new study led by Albert Einstein College of Medicine and Montefiore Health System confirms the findings of the large scale British trial of steroid use for COVID-19 patients and advances the research by answering several key questions: Which patients are most likely to benefit from steroid therapy? Could some of them be harmed? Can other formulations of steroids substitute for the agent studied in the British trial? The research was published today in the Journal of Hospital Medicine.
Published in this month’s edition of Toxicological Sciences are articles on biotransformation, toxicokinetics, and pharmacokinetics; developmental and reproductive toxicology; nanotoxicology; and more.
New instructions for using nasal sprays may help deliver at least eight times more inflammation-reducing medicine to diseased sinus tissues.
Researchers at the George Washington University and Albert Einstein College of Medicine published a review in the journal Nitric Oxide suggesting that nitric oxide treatment can be pivotal in the fight against SARS-CoV-2.
Sanford Burnham Prebys Medical Discovery Institute has received an award from the California Institute for Regenerative Medicine (CIRM) to advance promising drug candidates for COVID-19. The research team will test two existing drugs against “mini lungs in a dish” that have been infected with SARS-CoV-2.
Alzheimer's disease is a progressive disorder in which the nerve cells (neurons) in a person's brain and the connections among them degenerate slowly, causing severe memory loss, intellectual deficiencies, and deterioration in motor skills and communication.
Timothy Albertson has received a BARDA grant to lead a new clinical trial at UC Davis Health. The trial evaluates the efficacy, safety and tolerability of an antibody cocktail in hospitalized adult patients with COVID-19.
Malignant mesothelioma (MM) is a lethal cancer mainly caused by exposure to asbestos, for which, unfortunately, no current treatment has proven effective, despite the identification of several promising therapeutic targets over the years.
Johns Hopkins researchers have demonstrated that behavior therapy that exposes people to memories of their trauma doesn’t cause relapses of opioid or other drug use, and that PTSD severity and emotional problems have decreased after the first therapy session.
The August special issue of SLAS Discovery “High-Content Imaging and Informatics” features a special collection of original research and perspectives curated by guest editors Myles Fennell, Ph.D. and Paul A. Johnston, Ph.D of The Society of Biomolecular Imaging and Informatics.
The Weizmann Institute’s Dr. Ravid Straussman and colleagues developed a method that utilizes cellular signaling to determine the best treatment for a given tumor. The method can help tailor treatments and identify new drug-development targets. In fact, the team has already singled out a gene that serves as a target for treating BRCA-related breast cancers.
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (brand name Keytruda) in patients with advanced melanoma.
Dr. Jeffrey L. Cummings, UNLV research professor and a leading expert on Alzheimer’s disease clinical trials, led a five-year review of all Alzheimer’s drugs in the development pipeline. He says today there is more hope than ever that we'll one day solve Alzheimer’s. The paper, “Alzheimer's disease drug development pipeline: 2020,” was published this week in the journal Alzheimer's & Dementia: Translational Research & Clinical Interventions.
Cannabidiol, or CBD, may help reduce the cytokine storm and excessive lung inflammation that is killing many patients with COVID-19, researchers say.
Researchers at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) recently screened the first participant in the world for what is known as the AHEAD 3-45 study. This work is looking at a study medication, BAN2401, to determine if it can help prevent worsening memory and thinking among individuals who might be at risk for future decline. They are hoping this study finds that BAN2401 does just that and will ultimately help prevent Alzheimer’s disease.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
A prominent Australian pharmacologist has called for a new approach to treating COVID-19 as hopes fade of finding an effective vaccine or antiviral before the end of the year.
The American Society of Anesthesiologists firmly opposes the use of ketamine or any other sedative/hypnotic agent to chemically incapacitate someone for a law enforcement purpose and not for a legitimate medical reason. Ketamine is a potent analgesic, sedative and general anesthetic agent which can elevate blood pressure and heart rate, and can lead to confusion, agitation, delirium, and hallucinations. These effects can end in death when administered in a non-health care setting without appropriately trained medical personnel and necessary equipment.
Researchers at the Icahn School of Medicine report that roflumilast cream (ARQ-151), which contains a highly potent, selective phosphodiesterase-4 (PDE4) inhibitor demonstrated significant improvements in patients with psoriasis signs and symptoms in as early as two weeks. The phase 2b trial results showed that when patients with plaque psoriasis applied topical roflumilast once-daily they reported clear skin as well as improvement in itch and burden of disease. The results of the paper were published online today in The New England Journal of Medicine.
Researchers have developed a new drug that prevents blood clots without causing an increased risk of bleeding, a common side effect of all antiplatelet medications currently available. A new study published in the journal Science Translational Medicine describes the drug and its delivery mechanisms and shows that the drug is also an effective treatment for heart attack in animal models.
Researchers at the University of East Anglia and University of Manchester have made an important breakthrough that could lead to 'kinder' treatments for children with bone cancer, and save lives.
A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.
Harvard Medical School has named Robert Gentleman as founding executive director of the newly established Center for Computational Biomedicine. Gentleman, an accomplished statistician and computational scientist with extensive experience in academia and industry, most recently served as vice president of computational biology at the genetic testing company 23andMe.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right